DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis

Information source: Transport Pharmaceuticals
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Herpes Labialis

Intervention: iontophoretic acyclovir (Device)

Phase: Phase 2

Status: Completed

Sponsored by: Transport Pharmaceuticals

Official(s) and/or principal investigator(s):
Christopher M Hull, MD, Principal Investigator, Affiliation: University of Utah


Currently approved drugs for the treatment of herpes labialis (cold sores) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the site where the herpes virus is replicating. Iontophoresis uses electric current to enhance the delivery of drugs through the skin. This trial is testing a new iontophoretic device for the delivery of acyclovir cream to treat cold sores.

Clinical Details

Official title: A Multicenter, Placebo Controlled, Randomized, Double Blind, Subject Initiated Study of the Safety and Efficacy of a Single Topical Iontophoretic Application of Acyclovir 5% Cream With an Open Label Conventional Therapy Treatment Arm, and a Blinded Evaluator, for the Treatment of Recurrent Herpes Labialis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: Clinician assessed duration of the herpetic episode measured from time of treatment until lesion healed. Lesion assessments for a minimum of 5 consecutive days and a maximum of 10 consecutive days.

Secondary outcome:

Clinician assessed prevention of progression to a classical lesion

Clinician assessed duration of classical herpetic lesions.

Clinician assessed duration of the herpetic lesion (aborted lesions will be assigned a duration of lesion value of 0 for the purposes of the statistical analysis).

Clinician assessed duration of the herpetic lesion hard scab.

Examine the safety of iontophoretic application of acyclovir 5% cream.

All assessments for a minimum of 5 consecutive days and a maximum of 10 consecutive days.

Detailed description: This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of iontophoretically-applied acyclovir 5% cream for the treatment of herpes simplex labialis lesions including an open label arm using Zovirax (acyclovir) Cream 5% as per standard of care in the same patient population. Subjects who meet the eligibility requirements at the screening/randomization visit will be randomized in a 1: 1:1 ratio to one of the three treatment groups. After being enrolled and randomized into the study, subjects will be sent home with a locked kit containing the iontophoretic device with either active or placebo cream or a locked kit containing Zovirax Cream 5%. At first signs and/or symptoms of a recurrent herpetic episode (Stage 0 or 1, prodromal or erythema), the lesion will be confirmed by telephone interview with the subject, and upon confirmation of the lesion, the subject will be given the combination to the locked kit and instructed to begin treatment immediately, thereby initiating the Treatment Phase of the study. Subjects will be followed for at least 5 consecutive days post-treatment up until a maximum of 10 consecutive days post-treatment, until the herpes lesion is healed.


Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.


Inclusion Criteria: 1. Male or female subject 18-75 years of age 2. Female subject must be using a medically acceptable form of birth control during the study. Acceptable birth control measures are abstinence, oral contraceptive pills or patch, injectable contraception, barrier contraceptives (condom, diaphragm with spermicide), IUD, surgical (hysterectomy, tubal ligation), vasectomized partner, or natural post menopausal inability to conceive. 3. Subject must have a history of recurrent herpes labialis and report at least 3 recurrences during the preceding 12 months. 4. Subject must provide voluntary written informed consent to participate in this study. Exclusion Criteria: 1. Subjects with a pacemaker, or a history of cardiac arrhythmias or conduction abnormalities. Any subject with a medically confirmed history of cardiac arrhythmia including sinus arrhythmia, premature beat, heart block, atrial fibrillation, atrial flutter and pulsus alternans is to be excluded from the study. 2. Any evidence of active malignancy, immunodeficient disease, or use of immunomodifying drugs (e. g., systemic steroids) within 30 days prior to enrollment. Subjects who have completed therapy and are considered unlikely to relapse or who have had surgery and do not have any evidence of disease, are eligible for the study. 3. Subjects using topical steroids on or near the face or systemic (oral, intravenous) steroids within 30 days of enrollment; use of inhaled steroids does not exclude a subject from the study. 4. History of allergic or adverse response to acyclovir, or any related anti-viral drug, or the cream base. 5. In females of childbearing potential, a positive urine pregnancy test at time of screening. 6. Subject is considered unreliable or unable to understand or follow the protocol directions or is unable to comprehend or satisfactorily use the measurement scales as determined by investigator or designee at screening. 7. Subject has abnormal skin conditions that occur in the area ordinarily affected by cold sores which might affect the normal course of cold sores (e. g., eczema, psoriasis, albinism, or chronic vesiculobullous disorders). 8. Subject is currently enrolled in another clinical trial or has used an investigational drug/device within 30 days of enrollment. 9. Subject has previously participated in the current study (TPI-203). 10. Subject has used an anti-viral medication in the preceding 30 days. 11. Subject requires chronic use of analgesics, pain medication or non-steroidal anti-inflammatory agents (NSAIDs). If a subject is unlikely to get through the treatment phase of the protocol without requiring the use of analgesia for a chronic condition, e. g. back pain, recurrent daily headaches, the subject should be excluded. 12. Subject has a recent history of renal dysfunction or serious hepatic disease. Renal dysfunction encompasses both acute and chronic renal failure, the former resulting from the sudden loss of the ability of the kidneys to excrete wastes, concentrate urine, and conserve electrolytes and the latter the gradual and progressive loss of these capabilities. Examples of serious hepatic disease would include alcoholic liver disease, chronic hepatitis, autoimmune hepatitis and a variety of inherited diseases. The underlying cause of a documented recent mild increase in liver enzymes should be considered when deciding whether or not to exclude such a subject. 13. Subject has a history of alcoholism or drug abuse within the preceding 12 months. A subject with a history of a pathological pattern of alcohol use that causes a serious impairment of social or occupational functioning should be excluded. Such subjects may exhibit symptoms of tolerance and withdrawal along with other behavioral symptoms. 14. Subject is institutionalized.

Locations and Contacts

Radiant Research Birmingham, Birmingham, Alabama 35209, United States

Radiant Research Phoenix Southeast, Chandler, Arizona 85225, United States

Radiant Research Phoenix, Phoenix, Arizona 85013, United States

Radiant Research Scottsdale, Scottsdale, Arizona 85251, United States

Radiant Research San Diego, San Diego, California 92123, United States

Radiant Research Santa Rosa, Santa Rosa, California 95405, United States

Radiant Research St. Petersburg, Pinellas Park, Florida 33781, United States

Radiant Research Stuart, Stuart, Florida 34996, United States

Radiant Research West Palm, West Palm Beach, Florida 33407, United States

Radiant Research Atlanta, Atlanta, Georgia 30342, United States

Radiant Research Atlanta West, Atlanta, Georgia 30308, United States

Radiant Research Boise, Boise, Idaho 83704, United States

Radiant Research Chicago, Chicago, Illinois 60610, United States

Radiant Research Minneapolis, Edina, Minnesota 55435, United States

Radiant Research St. Louis, St. Louis, Missouri 63141, United States

Rochester Clinical Research, Inc., Rochester, New York 14609, United States

Radiant Research Cincinnati, Cincinnati, Ohio 45236, United States

Pediatric Clinical Trials International, Columbus, Ohio 43205, United States

Radiant Research Philadelphia, Philadelphia, Pennsylvania 19115, United States

Radiant Research Greer, Greer, South Carolina 29651, United States

J & S Studies, Inc., Bryan, Texas 77802, United States

Radiant Research Dallas North, Dallas, Texas 75231, United States

Radiant Research San Antonio, San Antonio, Texas 78229, United States

Univeristy of Utah Health Sciences, Salt Lake City, Utah 84132, United States

Dermatology & Laser Center NW, Bellingham, Washington 98225, United States

Radiant Research Tacoma, Lakewood, Washington 98499, United States

Additional Information

Sponsor company website

Starting date: April 2005
Last updated: June 30, 2006

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017